ConductScience.org, home

Paper1985243

Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma.

Moss TJ and 5 others. N Engl J Med, 1991. Cited by 232 papers, by iCite.

Cite this record

ConductScience Library. Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma. Papers, record 1985243. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/1985243

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Prognostic value of immunocytologic detection of bone marrow metastases in neuroblastoma.
PubMed
Journal
N Engl J Med
PubMed
Year
1991
PubMed
Publication types
Comparative Study, Journal Article, Research Support, Non-U.S. Gov't, Research Support, U.S. Gov't, P.H.S.
PubMed
Citations, by iCite
232
iCite
Relative citation ratio, by iCite
6.56
iCite
Revised in PubMed
2015-11-19
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Moss TJT J
2Reynolds CPC P
3Sather HNH N
4Romansky SGS G
5Hammond GDG D
6Seeger RCR C

Source PubMed

Download CSV of authors

Topics14

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Bone MarrowMajor topic
NeuroblastomaMajor topic
Age Factors
Antibodies, Monoclonal
Biopsy
Humans
Immunoenzyme Techniques
Neoplasm Metastasis
Neoplasm Staging
Prognosis
Reproducibility of Results
Sensitivity and Specificity
Trephining
Tumor Cells, Cultured

Source PubMed

Download CSV of topics

Grants5

Each grant PubMed's record writes, matched to the NIH project NIH's grant and paper links name for this paper, and each of those links the record does not write.

Grant, as the record writes itAgencyCountryNIH projectStated bySource
CA-16042NCI NIH HHSUnited StatesP01CA016042PubMed and NIHNIH RePORTER
CA-22794NCI NIH HHSUnited StatesR01CA022794PubMed and NIHNIH RePORTER
CA-27678NCI NIH HHSUnited StatesR10CA027678PubMed and NIHNIH RePORTER
P30CA016042NIHNIH RePORTER
U10CA027678NIHNIH RePORTER

Download CSV of grants

Cited by41

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 232 citations.

PMIDTitleJournalYearIn PapersSource
42818635Quantitative and sensitive neuroblastoma minimal residual disease detection using extrachromosomal DNA (ecDNA) breakpoints.bioRxiv2026https://conductscience.org/library/papers/42818635PubMed
40483504Epithelial-to-mesenchymal transition (EMT) and cancer metastasis: the status quo of methods and experimental models 2025.Mol Cancer2025https://conductscience.org/library/papers/40483504PubMed
40450177Evaluation of Minimal Residual Disease in Patients with Neuroblastoma.Mol Diagn Ther2025https://conductscience.org/library/papers/40450177PubMed
37834874A Multi-Color Flow Cytometric Assay for Quantifying Dinutuximab Binding to Neuroblastoma Cells in Tumor, Bone Marrow, and Blood.J Clin Med2023https://conductscience.org/library/papers/37834874PubMed
37284114
Evaluation of iodine-123-labeled metaiodobenzylguanidine single-photon emission computed tomography/computed tomography based on the International Society of Pediatric Oncology Europe Neuroblastoma score in children with neuroblastoma.
Quant Imaging Med Surg2023https://conductscience.org/library/papers/37284114PubMed
36176417Pro-metastatic and mesenchymal gene expression signatures characterize circulating tumor cells of neuroblastoma patients with bone marrow metastases and relapse.Front Oncol2022https://conductscience.org/library/papers/36176417PubMed
34445807Neuroblastoma GD2 Expression and Computational Analysis of Aptamer-Based Bioaffinity Targeting.Int J Mol Sci2021https://conductscience.org/library/papers/34445807PubMed
31214500Dynamics of Minimal Residual Disease in Neuroblastoma Patients.Front Oncol2019https://conductscience.org/library/papers/31214500PubMed
30613134Spotlight on dinutuximab in the treatment of high-risk neuroblastoma: development and place in therapy.Biologics2019https://conductscience.org/library/papers/30613134PubMed
26840262PHOX2B is a suppressor of neuroblastoma metastasis.Oncotarget2016https://conductscience.org/library/papers/26840262PubMed
25559819Bone marrow minimal residual disease was an early response marker and a consistent independent predictor of survival after anti-GD2 immunotherapy.J Clin Oncol2015https://conductscience.org/library/papers/25559819PubMed
25467309Bone marrows from neuroblastoma patients: an excellent source for tumor genome analyses.Mol Oncol2015https://conductscience.org/library/papers/25467309PubMed
24255631Morphologic alteration of metastatic neuroblastic tumor in bone marrow after chemotherapy.Korean J Pathol2013https://conductscience.org/library/papers/24255631PubMed
21971567Immunology and immunotherapy of neuroblastoma.Semin Cancer Biol2011https://conductscience.org/library/papers/21971567PubMed
21769682Cellular kinetics of neuroblastoma and the role of surgery.Pediatr Surg Int2011https://conductscience.org/library/papers/21769682PubMed
21037966Anti-GD2 Strategy in the Treatment of Neuroblastoma.Drugs Future2010https://conductscience.org/library/papers/21037966PubMed
20049927
Peripheral blood stem cell support for multiple cycles of dose intensive induction therapy is feasible with little risk of tumor contamination in advanced stage neuroblastoma: a report from the Childrens Oncology Group.
Pediatr Blood Cancer2010https://conductscience.org/library/papers/20049927PubMed
19411762Valpha24-invariant NKT cells mediate antitumor activity via killing of tumor-associated macrophages.J Clin Invest2009https://conductscience.org/library/papers/19411762PubMed
19401690
Consensus criteria for sensitive detection of minimal neuroblastoma cells in bone marrow, blood and stem cell preparations by immunocytology and QRT-PCR: recommendations by the International Neuroblastoma Risk Group Task Force.
Br J Cancer2009https://conductscience.org/library/papers/19401690PubMed
18834405The urokinase receptor (u-PAR)--a link between tumor cell dormancy and minimal residual disease in bone marrow?APMIS2008https://conductscience.org/library/papers/18834405PubMed

See all 41 cited byDownload CSV of cited by

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Trials
  • Comments and corrections
  • References
  • Genes
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/1985243

GET https://conductscience.org/api/papers/v1/1985243/cited_by?page=2